Making Best Practice, Every Day Practice
The large randomised controlled trial PARADIGM-HF showed that treatment with sacubitril/valsartan (Entresto) compared with enalapril reduced the risk of hospitalisation, cardiovascular and all-cause mortality and improved symptoms in patients with heart failure with reduced ejection fraction. This article describes the key results and how they can be applied in primary care.
A unique new e-platform for primary care
By continuing to this site you are confirming that you are a healthcare professional and are opting into the use of cookies.